March 20 (Reuters) - Glycomimetics Inc ::GLYCOMIMETICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 7.00 MILLION COMMON SHARES PRICED AT $17.00PER SHARE.
Full Article
March 19 (Reuters) - Glycomimetics Inc ::GLYCOMIMETICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.GLYCOMIMETICS INC - INTENDS TO OFFER AND SELL, SUBJECT TO MARKET CONDITIONS, 4.5 MILLION SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.GLYCOMIMETICS -TO USE PROCEEDS OF OFFERING TO CONDUCT PHASE 3 CLINICAL DEVELOPMENT PROGRAM FOR GMI-1271 IN PATIENTS WITH ACUTE MYELOID LEUKEMIA.GLYCOMIMETICS - TO USE NET PROCEEDS OF OFFERING TO CONDUCT, COMPLETE ITS PLANNED PHASE 3 CLINICAL DEVELOPMENT PROGRAM FOR GMI-1271.
Full Article
March 6 (Reuters) - Glycomimetics Inc ::GLYCOMIMETICS REPORTS FOURTH QUARTER AND YEAR-END 2017 RESULTS.GLYCOMIMETICS INC QUARTERLY LOSS PER SHARE $0.27.GLYCOMIMETICS INC - AS OF DEC 31, 2017, HAD CASH AND CASH EQUIVALENTS OF $123.9 MILLION AS COMPARED TO $40.0 MILLION AS OF DECEMBER 31, 2016.
Full Article
March 5 (Reuters) - Glycomimetics Inc ::GLYCOMIMETICS ANNOUNCES DESIGN OF PHASE 3 CLINICAL TRIAL FOR GMI-1271 IN RELAPSED/REFRACTORY AML.GLYCOMIMETICS INC - PRIMARY ENDPOINT FOR SINGLE PIVOTAL CLINICAL TRIAL WILL BE OVERALL SURVIVAL.GLYCOMIMETICS INC - MULTIPLE CLINICAL READOUTS PLANNED STARTING YEAR-END 2018 AND THROUGH 2019 AND 2020.GLYCOMIMETICS INC - IN EARLY 2019, ANTICIPATE TOPLINE DATA FROM PROOF-OF-CONCEPT TRIAL OF GMI-1271 IN MULTIPLE MYELOMA.
Full Article
Feb 8 (Reuters) - Glycomimetics Inc ::GLYCOMIMETICS ENTERS INTO AGREEMENT WITH HOVON TO INITIATE STUDY STARTUP ACTIVITIES FOR PLANNED CLINICAL TRIAL OF GMI-1271 AND DECITABINE IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WHO ARE UNFIT FOR CHEMOTHERAPY.GLYCOMIMETICS INC - ON TRACK TO DISCLOSE DETAILS FOR DESIGN OF PHASE 3 TRIAL IN RELAPSED/REFRACTORY AML PATIENTS DURING 2017 YEAR-END EARNINGS CALL.GLYCOMIMETICS INC - HOVON INTENDS TO ENROLL APPROXIMATELY 140 PATIENTS IN CLINICAL TRIAL OF GMI-1271 AND DECITABINE.
Full Article
Nov 8 (Reuters) - Glycomimetics Inc :Glycomimetics reports program updates and third quarter 2017 results.Glycomimetics inc - phase 3 clinical trial of rivipansel on track for completion in second half of 2018.Glycomimetics inc qtrly loss per share $0.24.Glycomimetics inc - research and development expenses decreased slightly to $5.8 million for quarter ended september 30, 2017 as compared to $5.9 million.
Full Article
Sept 28 (Reuters) - GlycoMimetics Inc :GlycoMimetics Inc says files for mixed shelf of upto $250.0 million - SEC filing.
Full Article
June 5 (Reuters) - Glycomimetics Inc :Glycomimetics presents updated data from ongoing phase 1/2 clinical trial of GMI-1271 in patients with acute myeloid leukemia at ASCO 2017 annual meeting.Glycomimetics Inc says GMI-1271 continues to be well tolerated in combination with induction chemotherapy.Glycomimetics -remission rates continue to be higher than historical controls & induction-related mortality continues to be lower than historical controls.Glycomimetics Inc - in study only one case of severe (grade 3/4) mucositis reported among 79 patients receiving high-intensity induction chemotherapy.Glycomimetics Inc - relapsed/refractory patients with more blasts expressing e-selectin ligand were more likely to achieve complete response in study.
Full Article
May 24 (Reuters) - Glycomimetics Inc :Glycomimetics announces pricing of public offering of common stock.Says public offering of 7.00 million common shares priced at $11.50per share.
Full Article
May 24 (Reuters) - Glycomimetics Inc :Glycomimetics Inc - co terminated its sales agreement, dated March 1, 2016, with Cowen and Company.
Full Article
Earnings vs. 
Estimates